Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes

Md Yusof, MY orcid.org/0000-0003-3131-9121, Shaw, D, Rawstron, A et al. (2 more authors) (2016) Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes. In: Annals of the Rheumatic Diseases. Annual European Congress of Rheumatology (EULAR 2016), 08-11 Jun 2016, London, UK. BMJ Publishing Group , p. 296.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: (c) 2016, Published by the BMJ Publishing Group Limited. This is an author produced version of an abstract published in Annals of the Rheumatic Diseases. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 15 July 2016
  • Published: June 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Funding Information:
FunderGrant number
NIHR National Inst Health ResearchDRF-2014-07-155
Depositing User: Symplectic Publications
Date Deposited: 03 Apr 2019 14:52
Last Modified: 03 Apr 2019 14:52
Status: Published
Publisher: BMJ Publishing Group
Identification Number: https://doi.org/10.1136/annrheumdis-2016-eular.5947
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)